Case Report
Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy
Table 1
Characteristics of patients reported to have achieved sustained transfusion independence after stopping iron chelation therapy.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AML, acute myelogenous leukemia; DFO, deferoxamine; DFX, deferasirox; Int., intermediate; FAB, French American British; hydrea, hydroxyurea; IPSS, International Prognostic Scoring System; ICT, iron chelation therapy; MDS, myelodysplastic syndrome; mo., months; MPN, myeloproliferative neoplasm; PMF, primary myelofibrosis; RA, refractory anemia; RAEB, refractory anemia with excess blasts; MDS, myelodysplastic syndromes; MPN, myeloproliferative neoplasm; NR, not reported; PMF, primary myelofibrosis; RARS-T, refractory anemia with ring sideroblasts and thrombocytosis; TI, transfusion independence; WHO, World Health Organization; +, indicates ongoing TI. 1TI achieved 15 months after chelation was stopped. 2Duration of TI after stopping chelation for cases 1–5 was reported as a range only. 3Hydroxyurea was given after stopping chelation due to progression to AML. 4Dupriez score (Dupriez et al., 1996 [45]). 5IPSS score for MDS (Greenberg et al., 1997 [1]). 6No response to EPO. |